TimesSquare Capital Management LLC Sells 24,060 Shares of Xenon Pharmaceuticals Inc. $XENE

TimesSquare Capital Management LLC decreased its stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 4.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 532,740 shares of the biopharmaceutical company’s stock after selling 24,060 shares during the period. TimesSquare Capital Management LLC owned about 0.69% of Xenon Pharmaceuticals worth $23,877,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in XENE. Goldman Sachs Group Inc. lifted its position in Xenon Pharmaceuticals by 7.9% during the first quarter. Goldman Sachs Group Inc. now owns 442,732 shares of the biopharmaceutical company’s stock valued at $14,854,000 after purchasing an additional 32,486 shares during the period. Jump Financial LLC bought a new position in Xenon Pharmaceuticals during the second quarter valued at approximately $532,000. Sei Investments Co. bought a new position in Xenon Pharmaceuticals during the second quarter valued at approximately $711,000. The Manufacturers Life Insurance Company bought a new position in Xenon Pharmaceuticals during the second quarter valued at approximately $816,000. Finally, Alliancebernstein L.P. lifted its position in Xenon Pharmaceuticals by 14.2% during the second quarter. Alliancebernstein L.P. now owns 1,518,527 shares of the biopharmaceutical company’s stock valued at $47,530,000 after purchasing an additional 189,141 shares during the period. Institutional investors own 95.45% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on XENE shares. HC Wainwright increased their price objective on shares of Xenon Pharmaceuticals from $53.00 to $74.00 and gave the company a “buy” rating in a research report on Tuesday, March 10th. Needham & Company LLC lowered their price objective on shares of Xenon Pharmaceuticals from $80.00 to $78.00 and set a “buy” rating on the stock in a research report on Friday, May 8th. Wells Fargo & Company restated an “overweight” rating and set a $69.00 price objective on shares of Xenon Pharmaceuticals in a research report on Sunday, May 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a research report on Wednesday, April 8th. Finally, Jefferies Financial Group set a $100.00 price target on shares of Xenon Pharmaceuticals in a research report on Monday, March 9th. Two analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Xenon Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $77.07.

Insiders Place Their Bets

In other Xenon Pharmaceuticals news, CEO Ian Mortimer sold 270,000 shares of the stock in a transaction that occurred on Monday, March 9th. The shares were sold at an average price of $60.33, for a total value of $16,289,100.00. Following the transaction, the chief executive officer directly owned 6,000 shares in the company, valued at approximately $361,980. This trade represents a 97.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Christopher John Kenney sold 2,771 shares of the stock in a transaction that occurred on Tuesday, March 10th. The stock was sold at an average price of $60.11, for a total transaction of $166,564.81. Following the completion of the transaction, the insider owned 4,729 shares in the company, valued at $284,260.19. The trade was a 36.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 296,707 shares of company stock worth $17,845,365. Company insiders own 4.07% of the company’s stock.

Xenon Pharmaceuticals Trading Up 0.6%

XENE opened at $54.05 on Wednesday. Xenon Pharmaceuticals Inc. has a 1-year low of $28.19 and a 1-year high of $63.95. The company has a market capitalization of $5.23 billion, a PE ratio of -11.50 and a beta of 0.65. The firm’s 50 day simple moving average is $56.54 and its two-hundred day simple moving average is $47.35.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.17) earnings per share for the quarter, hitting the consensus estimate of ($1.17). During the same quarter in the prior year, the company earned ($0.83) earnings per share. Equities analysts forecast that Xenon Pharmaceuticals Inc. will post -4.88 earnings per share for the current fiscal year.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.